Race Oncology Ltd is advancing the development of a reformulated chemotherapy drug aimed at reducing severe side effects, particularly cardiac-related risks, while preserving or improving efficacy. In this episode of After Market with Jonathan Jackson, CEO and managing director Daniel Tillett highlighted the drug’s potential to work alongside anthracyclines, a common class of chemotherapy agents, to enhance patient safety and treatment outcomes. The company is preparing for clinical trials to evaluate the drug’s performance in human subjects.

Ver todos los episodios